A sensitive, specific, noncompetitive, sandwich-type radioimmunoassayfor carcinoembryonic antigen (CEA) has been developed in our laboratoryl which canbe performed conveniently. The assay involves two monoclonal antib...A sensitive, specific, noncompetitive, sandwich-type radioimmunoassayfor carcinoembryonic antigen (CEA) has been developed in our laboratoryl which canbe performed conveniently. The assay involves two monoclonal antibodies, selectedfor high affinity and specificity and also for reaction against antigenic sites on CEAthat are distal from each other. One of these antibodies was labeled with 1251 andthe other was conjugated covalently to biotin. Polystyrene tubes were conjugatedcovalently to avidin. These tubes represent a rapid, simple method for separating theCEA-bound antibody from the free antibody. The biotin-antibody-CEA-"’I-labeledantibody complexes bind to the tubes and CEA concentration is directly related tocounts per minute. This assay can detect the CEA at a concentration of 0.22 ig/L inserum.展开更多
采用包被管分离技术,利用两株抗PAP单克隆抗体,双位点夹心免疫放射分析方法测量人血清中PAP含量。结果表明,该试剂盒分析灵敏度为0.1μg/L;批内变异系数为(8.8～9.6)％;批间变异系数为(7.7～12.3)％;回收率为(96.3～105.0)％;标准曲线...采用包被管分离技术,利用两株抗PAP单克隆抗体,双位点夹心免疫放射分析方法测量人血清中PAP含量。结果表明,该试剂盒分析灵敏度为0.1μg/L;批内变异系数为(8.8～9.6)％;批间变异系数为(7.7～12.3)％;回收率为(96.3～105.0)％;标准曲线范围为2.5～200.0μg/L。与DPC公司CAC PAP IR-MA试剂盒进行方法学比较,相关系数r=0.909。展开更多
AIM: To examine the concentration of a new antigen SC6 (SC6-Ag) recognized by monoclonal antibody (MAb)in patients with pancreatic cancer and other malignant or benign diseases and to understand whether SC6-Ag has any...AIM: To examine the concentration of a new antigen SC6 (SC6-Ag) recognized by monoclonal antibody (MAb)in patients with pancreatic cancer and other malignant or benign diseases and to understand whether SC6-Ag has any clinical significance in distinguishing pancreatic cancer from other gastrointestinal diseases.METHODS: Six hundred and ninety-five serum specimens obtained from 115 patients with pancreatic cancer, 154 patients with digestive cancer and 95patients with non-digestive cancer were used and classified in this study. Serum specimens obtained from 140 patients with benign digestive disease and 89 patients with non-benign digestive disease served as controls. Ascites was tapped from 16 pancreatic cancer patients, 19 hepatic cancer patients, 16 colonic cancer patients, 10 gastric cancer and 6 severe necrotic pancreatitis patients. The samples were quantitated by solid-phase radioimmunoassay. The cut-off values (CV)of 41, 80, and 118 U/mL were used.RESULTS: The average intra- and interassay CV detected by immunoradiometric assay of SC6-Ag was 5.4% and 8.7%, respectively. The sensitivity and specificity were 73.0% and 90.9% respectively. The levels in most malignant and benign cases were within the normal upper limit. Among the 16 pancreatic cancer cases, the concentration of SC6-Ag in ascites was over the normal range in 93.8% patients. There was no significant difference in the concentration of SC6-Ag.Decreased expression of SC6-Ag in sera was significantly related to tumor differentiation. The concentration of SC6-Ag was higher in patients before surgery than after surgery. The specificity of SC6-Ag and CA19-9 was significantly higher than that of ultrasound and computer tomography (CT) in pancreatic cancer patients. Higher positive predictive values were indicated in 92.3% SC6-Ag and 88.5% CA19-9, but lower in 73.8% ultrasound and 76.2% CT.CONCLUSION: The combined test of SC6-Ag and CA19-9 may improve the diagnostic rate of primary cancer. The detection of SC6-Ag is valuable in the diagnosis of pancreatic cancer before and after surgery.展开更多
文摘A sensitive, specific, noncompetitive, sandwich-type radioimmunoassayfor carcinoembryonic antigen (CEA) has been developed in our laboratoryl which canbe performed conveniently. The assay involves two monoclonal antibodies, selectedfor high affinity and specificity and also for reaction against antigenic sites on CEAthat are distal from each other. One of these antibodies was labeled with 1251 andthe other was conjugated covalently to biotin. Polystyrene tubes were conjugatedcovalently to avidin. These tubes represent a rapid, simple method for separating theCEA-bound antibody from the free antibody. The biotin-antibody-CEA-"’I-labeledantibody complexes bind to the tubes and CEA concentration is directly related tocounts per minute. This assay can detect the CEA at a concentration of 0.22 ig/L inserum.
文摘采用包被管分离技术,利用两株抗PAP单克隆抗体,双位点夹心免疫放射分析方法测量人血清中PAP含量。结果表明,该试剂盒分析灵敏度为0.1μg/L;批内变异系数为(8.8～9.6)％;批间变异系数为(7.7～12.3)％;回收率为(96.3～105.0)％;标准曲线范围为2.5～200.0μg/L。与DPC公司CAC PAP IR-MA试剂盒进行方法学比较,相关系数r=0.909。
文摘AIM: To examine the concentration of a new antigen SC6 (SC6-Ag) recognized by monoclonal antibody (MAb)in patients with pancreatic cancer and other malignant or benign diseases and to understand whether SC6-Ag has any clinical significance in distinguishing pancreatic cancer from other gastrointestinal diseases.METHODS: Six hundred and ninety-five serum specimens obtained from 115 patients with pancreatic cancer, 154 patients with digestive cancer and 95patients with non-digestive cancer were used and classified in this study. Serum specimens obtained from 140 patients with benign digestive disease and 89 patients with non-benign digestive disease served as controls. Ascites was tapped from 16 pancreatic cancer patients, 19 hepatic cancer patients, 16 colonic cancer patients, 10 gastric cancer and 6 severe necrotic pancreatitis patients. The samples were quantitated by solid-phase radioimmunoassay. The cut-off values (CV)of 41, 80, and 118 U/mL were used.RESULTS: The average intra- and interassay CV detected by immunoradiometric assay of SC6-Ag was 5.4% and 8.7%, respectively. The sensitivity and specificity were 73.0% and 90.9% respectively. The levels in most malignant and benign cases were within the normal upper limit. Among the 16 pancreatic cancer cases, the concentration of SC6-Ag in ascites was over the normal range in 93.8% patients. There was no significant difference in the concentration of SC6-Ag.Decreased expression of SC6-Ag in sera was significantly related to tumor differentiation. The concentration of SC6-Ag was higher in patients before surgery than after surgery. The specificity of SC6-Ag and CA19-9 was significantly higher than that of ultrasound and computer tomography (CT) in pancreatic cancer patients. Higher positive predictive values were indicated in 92.3% SC6-Ag and 88.5% CA19-9, but lower in 73.8% ultrasound and 76.2% CT.CONCLUSION: The combined test of SC6-Ag and CA19-9 may improve the diagnostic rate of primary cancer. The detection of SC6-Ag is valuable in the diagnosis of pancreatic cancer before and after surgery.
